The test, called LifeKit Prevent, analyzes microbial genomic biomarkers in stool samples that are strongly associated with specific stages of CRC progression.
Chia Tai Tianqing Pharmaceutical Group has agreed to copromote Genetron's HCCscreen test in hospitals where the pharma firm has an established presence.
Hologic said that Biotheranostics' PCR-based gene expression tests have been validated in large studies in areas of oncology with high growth potential.
The companies said Tuesday that they are pursuing a clinical trial utilizing their respective liquid biopsy assays on clinical samples from lung cancer patients.
Over the next year or so, the investigators plan to sequence the genomes of 3,000 patients with cancer, heart disease, diabetes, or neurological disorders.
Illumina's acquisition of Grail, Exact Sciences' acquisition of Thrive Earlier Detection, and Invitae's acquisition of ArcherDx all topped out at over $1 billion.
In a note to investors, Piper Sandler analysts wrote that the upgrade reflects increased confidence in Grail and Illumina's core next-generation sequencing business.
The Universities of Southampton and Leeds will lead the project with participation from Johnson & Johnson, Roche, Oncimmune, BC Platforms, Inivata, and NHS England.
The rating increase follows Oncocyte's Chinese distribution deal for its DetermaRx lung cancer treatment stratification test with Burning Rock Biotech.
The company offers a blood test that detects human papillomavirus-related cancer by measuring tumor tissue-modified viral DNA using droplet digital PCR.
